This company listing is no longer active
Mersana Therapeutics (0M40) Stock Overview
A clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
0M40 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Mersana Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.40 |
| 52 Week High | US$31.63 |
| 52 Week Low | US$4.52 |
| Beta | 0.43 |
| 1 Month Change | 6.72% |
| 3 Month Change | n/a |
| 1 Year Change | -19.68% |
| 3 Year Change | -80.46% |
| 5 Year Change | -93.23% |
| Change since IPO | -91.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0M40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.8% | 0.8% | -1.7% |
| 1Y | -19.7% | -7.6% | -0.6% |
Return vs Industry: 0M40 exceeded the German Biotechs industry which returned -30.1% over the past year.
Return vs Market: 0M40 underperformed the German Market which returned 14.5% over the past year.
Price Volatility
| 0M40 volatility | |
|---|---|
| 0M40 Average Weekly Movement | 71.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 0M40's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0M40's weekly volatility has increased from 42% to 72% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 102 | Marty Huber | www.mersana.com |
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175.
Mersana Therapeutics, Inc. Fundamentals Summary
| 0M40 fundamental statistics | |
|---|---|
| Market cap | €123.94m |
| Earnings (TTM) | -€59.74m |
| Revenue (TTM) | €28.29m |
Is 0M40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0M40 income statement (TTM) | |
|---|---|
| Revenue | US$33.18m |
| Cost of Revenue | US$69.03m |
| Gross Profit | -US$35.85m |
| Other Expenses | US$34.23m |
| Earnings | -US$70.08m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.02 |
| Gross Margin | -108.04% |
| Net Profit Margin | -211.21% |
| Debt/Equity Ratio | 0% |
How did 0M40 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 23:40 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mersana Therapeutics, Inc. is covered by 3 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Konstantinos Aprilakis | Stifel, Equities Research |
| Tara Bancroft | TD Cowen |